In a report released yesterday, Eun Yang from Jefferies reiterated a Buy rating on Array Biopharma (NASDAQ: ARRY), with a price target of $18. The company’s shares opened today at $13.92.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.5% and a 51.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Alexion Pharmaceuticals, and Amag Pharmaceuticals.
Currently, the analyst consensus on Array Biopharma is a Strong Buy with an average price target of $24.20, a 73.9% upside from current levels. In a report released yesterday, Cowen & Co. also reiterated a Buy rating on the stock with a $22 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.21 and a one-year low of $8.50. Currently, Array Biopharma has an average volume of 2.47M.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. Last month, Kyle Lefkoff, a Director at ARRY sold 50,000 shares for a total of $872,500.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.
Read More on ARRY:
